Reference:
Kleinschmidt-DeMasters BK, Lopes
MB, Prayson RA. An algorithmic approach to sellar region masses. Arch Pathol
Lab Med. 2015;139(3):356-372.
I discuss issues pertaining to the practice of neuropathology -- including nervous system tumors, neuroanatomy, neurodegenerative disease, muscle and nerve disorders, ophthalmologic pathology, neuro trivia, neuropathology gossip, job listings and anything else that might be of interest to a blue-collar neuropathologist.
Neuropathology Blog has run its course. It's been a fantastic experience authoring this blog over many years. The blog has been a source...
2 comments:
Due to the lack of standards and a validated cut-off for p53 as well as some concerns with Ki67 cut off value for atypical pituitary adenomas there is still some confusion. Another problem with atypical adenomas is widely criticized lack of definition of invasiveness and incorporation of this parameter in 2004 WHO classification. The clinico-pathological studies show a wide range ( 2.7% - 15%) of atypical adenomas, according to different interpretations of its definition.
In Europe there is a growing interest in novel clinicopathological classification proposed by Jacqueline Truillas group.The classification takes into account tumour invasion and proliferation and seems to have honest clinical validation. It’s a new look at an quite known theme.
A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up.
Trouillas J, Roy P, Sturm N, Dantony E,et al. Acta Neuropathol. 2013 Jul;126(1):123-35. doi: 10.1007/s00401-013-1084-y. Epub 2013 Feb 12.
My son had a macroprolactinoma initially misdiagnosed as non functioning so tumor was partially resected and pathology performed. I do not have access to read the WHO 2017 pituitary guidelines but I do understand they have dropped "atypical" and provided new standards for considering a tumor aggressive. My son's pathology showed Ki67 of 3.98% with mitosis less than 1 per 10 HPF. No p53 testing was done. His tumor was invasive, encasing his left carotid artery. Based upon what you may know of the WHO 2017 changes, what do you think of these results?
Post a Comment